- Home
- NRIX vs CMPX Comparison
NRIX vs CMPX Comparison
Compare NRIX & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRIX
- CMPX
- Stock Information
- Founded
- NRIX 2009
- CMPX 2014
- Country
- NRIX United States
- CMPX United States
- Employees
- NRIX N/A
- CMPX N/A
- Industry
- NRIX Biotechnology: Pharmaceutical Preparations
- CMPX Biotechnology: Pharmaceutical Preparations
- Sector
- NRIX Health Care
- CMPX Health Care
- Exchange
- NRIX Nasdaq
- CMPX Nasdaq
- Market Cap
- NRIX 750.4M
- CMPX 730.9M
- IPO Year
- NRIX 2020
- CMPX N/A
- Fundamental
- Price
- NRIX $12.00
- CMPX $4.03
- Analyst Decision
- NRIX Strong Buy
- CMPX Strong Buy
- Analyst Count
- NRIX 14
- CMPX 7
- Target Price
- NRIX $26.64
- CMPX $14.71
- AVG Volume (30 Days)
- NRIX 1.7M
- CMPX 1.9M
- Earning Date
- NRIX 10-09-2025
- CMPX 11-11-2025
- Dividend Yield
- NRIX N/A
- CMPX N/A
- EPS Growth
- NRIX N/A
- CMPX N/A
- EPS
- NRIX N/A
- CMPX N/A
- Revenue
- NRIX $83,687,000.00
- CMPX N/A
- Revenue This Year
- NRIX $58.48
- CMPX N/A
- Revenue Next Year
- NRIX N/A
- CMPX N/A
- P/E Ratio
- NRIX N/A
- CMPX N/A
- Revenue Growth
- NRIX 48.32
- CMPX N/A
- 52 Week Low
- NRIX $8.18
- CMPX $1.27
- 52 Week High
- NRIX $29.56
- CMPX $4.86
- Technical
- Relative Strength Index (RSI)
- NRIX 66.65
- CMPX 53.40
- Support Level
- NRIX $10.28
- CMPX $3.86
- Resistance Level
- NRIX $11.70
- CMPX $4.15
- Average True Range (ATR)
- NRIX 0.79
- CMPX 0.29
- MACD
- NRIX 0.24
- CMPX -0.05
- Stochastic Oscillator
- NRIX 98.06
- CMPX 21.67
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
About CMPX Compass Therapeutics Inc.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.